<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129818</url>
  </required_header>
  <id_info>
    <org_study_id>CFAM810A2404</org_study_id>
    <nct_id>NCT00129818</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding</brief_title>
  <official_title>A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day
      (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with
      and without a reported history of genital herpes and with or without herpes virus type 1
      (HSV-1) seropositivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Group 1. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients with a history of clinical genital herpes lesions</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Group 2. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients without a history of clinical genital herpes lesions</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of HSV DNA PCR positive days without lesions in HSV-2 seropositive patients with and without a history of clinical genital herpes lesions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantitative HSV DNA PCR, during the days with positive HSV-2 shedding.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to the first recurrence of genital herpes and number of genital herpes recurrence episodes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oral HSV-1 and/or HSV-2 shedding in HSV-1 and HSV-2 seropositive patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of HSV DNA PCR positive days with lesions in HSV-2 seropositive patients with and without a history of clinical genital herpes lesions</measure>
  </secondary_outcome>
  <condition>Genital Herpes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant females at least 18 years of age with HSV-2 seropositive
             serology with or without history of clinically diagnosed recurrent genital herpes

        Exclusion Criteria:

          -  Pregnancy

          -  History of renal dysfunction

          -  Use of immunosuppressive therapy, including steroids (other than topical or inhaled),
             or use of probenecid

          -  Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Center for Clinical STD Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Clinical Research - Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynne Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westover Heights Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington - Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2005</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <keyword>Genital herpes</keyword>
  <keyword>viral shedding</keyword>
  <keyword>famciclovir</keyword>
  <keyword>Symptomatic genital herpes</keyword>
  <keyword>Asymptomatic genital herpes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famciclovir</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

